Earnings Feed
Start Free
Kiniksa Pharmaceuticals International, plc·4

Apr 3, 4:41 PM ET

Tessari Eben 4

4 · Kiniksa Pharmaceuticals International, plc · Filed Apr 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Kiniksa (KNSA) CSO Eben Tessari Exercises Options & Receives Awards

What Happened
Eben Tessari, Chief Strategy Officer of Kiniksa Pharmaceuticals (KNSA), completed multiple equity transactions reported on Apr 3, 2026. Key items:

  • Acquired 365 shares through the company ESPP on Jan 15, 2026 at $24.16 per share (total $8,818; reported as exempt under Rule 16b-3(e)).
  • On Apr 1, 2026 Tessari exercised/converted derivatives to acquire 5,975 shares (Form shows acquisition but no per-share price listed).
  • To cover tax/exercise obligations, 1,756 shares were withheld/disposed at $48.13 per share (proceeds/withholding value shown as $84,516).
  • The filing also shows multiple new awards/grants on Apr 1, 2026 totaling 58,100 units (33,200 + 8,300 + 16,600) reported as awards/derivatives at $0.00 (RSUs/PSUs/options per footnotes).
  • Additional conversion/exercise entries show dispositions of 1,773; 1,745; and 2,457 shares (reported with $0.00 values) consistent with share settlement/conversion activity.

Key Details

  • Transaction dates: Jan 15, 2026 (ESPP purchase); Apr 1, 2026 (exercises, awards, tax withholding). Filing date: Apr 3, 2026.
  • Prices/values shown: ESPP 365 shares @ $24.16 = $8,818; tax withholding 1,756 shares @ $48.13 = $84,516. Several derivative entries list $0.00 (typical for RSU/PSU settlement or net share issuance).
  • Shares owned after the transactions: not disclosed in the provided filing excerpt.
  • Notable footnotes: F1 confirms ESPP purchase was exempt under Rule 16b-3(e); F2–F9 describe that awards include RSUs and PSUs (vesting schedules and performance conditions) and an option vesting schedule (vesting commencement dates and vesting cadence). F6 notes PSU payout may be up to 200% of one share depending on performance.
  • Timeliness: Apr 1 transactions were filed promptly (Form filed Apr 3). The Jan 15 ESPP purchase was included voluntarily in this filing per footnote F1.

Context

  • The Apr 1 entries indicate exercises/conversions of equity awards and the simultaneous withholding/surrender of some shares to satisfy tax or exercise payment obligations (code F = tax/exercise payment). This is a common administrative step and does not necessarily signal an open-market sale.
  • Awards listed at $0.00 are typical for RSU/PSU grants or option awards (they represent rights to future shares subject to vesting/performance rather than open-market purchases).
  • The filing is factual reporting of insider activity; it does not state motivations. Purchases (ESPP) can be interpreted as a modest insider buy, while exercises/awards mostly reflect standard compensation and vesting activity.

Insider Transaction Report

Form 4
Period: 2026-01-15
Kiniksa Pharmaceuticals International, plcKNSA
Tessari Eben
CHIEF STRATEGY OFFICER
Transactions
  • Award

    Class A Ordinary Share

    [F1]
    2026-01-15$24.16/sh+365$8,818→ 17,031 total
  • Exercise/Conversion

    Class A Ordinary Share

    [F2]
    2026-04-01+5,975→ 23,006 total
  • Tax Payment

    Class A Ordinary Share

    2026-04-01$48.13/sh−1,756$84,516→ 21,250 total
  • Award

    Share Option

    [F3]
    2026-04-01+33,200→ 33,200 total
    Exercise: $48.13Exp: 2036-03-31→ Class A Ordinary Share (33,200 underlying)
  • Award

    Restricted Share Unit

    [F2][F4]
    2026-04-01+8,300→ 8,300 total
    → Class A Ordinary Share (8,300 underlying)
  • Award

    Performance Share Unit

    [F5][F6]
    2026-04-01+16,600→ 16,600 total
    → Class A Ordinary Share (16,600 underlying)
  • Exercise/Conversion

    Restricted Share Unit

    [F2][F7]
    2026-04-01−1,773→ 1,772 total
    → Class A Ordinary Share (1,773 underlying)
  • Exercise/Conversion

    Restricted Share Unit

    [F2][F8]
    2026-04-01−1,745→ 3,490 total
    → Class A Ordinary Share (1,745 underlying)
  • Exercise/Conversion

    Restricted Share Unit

    [F2][F9]
    2026-04-01−2,457→ 7,371 total
    → Class A Ordinary Share (2,457 underlying)
Footnotes (9)
  • [F1]The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2025 to January 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e).
  • [F2]Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
  • [F3]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2026.
  • [F4]The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter.
  • [F5]Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.
  • [F6]Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply.
  • [F7]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023.
  • [F8]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024.
  • [F9]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025.
Signature
/s/ Douglas Barry, Attorney-in-Fact|2026-04-03

Documents

1 file
  • 4
    form4-04032026_080412.xmlPrimary